These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 22508952)

  • 1. US judge fines Johnson & Johnson $1.1bn for misleading marketing of risperidone.
    Tanne JH
    BMJ; 2012 Apr; 344():e2772. PubMed ID: 22508952
    [No Abstract]   [Full Text] [Related]  

  • 2. Johnson & Johnson pays $181m for misleading marketing of risperidone.
    Tanne JH
    BMJ; 2012 Sep; 345():e5916. PubMed ID: 22945959
    [No Abstract]   [Full Text] [Related]  

  • 3. Johnson & Johnson to pay $2.2bn to settle charges of false marketing on three drugs.
    Kmietowicz Z
    BMJ; 2013 Nov; 347():f6696. PubMed ID: 24196512
    [No Abstract]   [Full Text] [Related]  

  • 4. Risperidone use in a teaching hospital during its first year after market approval: economic and clinical implications.
    Carter CS; Mulsant BH; Sweet RA; Maxwell RA; Coley K; Ganguli R; Branch R
    Psychopharmacol Bull; 1995; 31(4):719-25. PubMed ID: 8851645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. US drug companies paid $15bn in fines for fraudulent marketing in past five years.
    Tanne JH
    BMJ; 2010 Dec; 341():c7360. PubMed ID: 21177361
    [No Abstract]   [Full Text] [Related]  

  • 6. Shifting terrain in the regulation of off-label promotion of pharmaceuticals.
    Mello MM; Studdert DM; Brennan TA
    N Engl J Med; 2009 Apr; 360(15):1557-66. PubMed ID: 19357413
    [No Abstract]   [Full Text] [Related]  

  • 7. The House of Commons Health Committee: 'The Influence of the Pharmaceutical Industry'. Too much too late?
    Kerwin R
    J Psychopharmacol; 2007 Mar; 21(2):131-3. PubMed ID: 17329287
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmaceutical marketing and the new social media.
    Greene JA; Kesselheim AS
    N Engl J Med; 2010 Nov; 363(22):2087-9. PubMed ID: 21105789
    [No Abstract]   [Full Text] [Related]  

  • 9. Major issues in marketing regulation.
    Pines WL
    Food Drug Law J; 1997; 52(3):297-302. PubMed ID: 10343028
    [No Abstract]   [Full Text] [Related]  

  • 10. Direct-to-consumer genetic tests, government oversight, and the First Amendment: what the government can (and can't) do to protect the public's health.
    Javitt GH; Stanley E; Hudson K
    Oklahoma Law Rev; 2004; 57(2):251-302. PubMed ID: 15658034
    [No Abstract]   [Full Text] [Related]  

  • 11. Prescription drug advertising--should states regulate what is false and misleading?
    Shaeffer J
    Food Drug Law J; 2003; 58(4):629-48. PubMed ID: 15027454
    [No Abstract]   [Full Text] [Related]  

  • 12. Disease-branding and drug-mongering: could pharmaceutical industry promotional practices result in tort liability?
    Cetel JS
    Seton Hall Law Rev; 2012; 42(2):643-702. PubMed ID: 22708139
    [No Abstract]   [Full Text] [Related]  

  • 13. Pfizer Australia is fined for misleading promotion of celecoxib.
    Burton B
    BMJ; 2005 May; 330(7502):1230. PubMed ID: 15920126
    [No Abstract]   [Full Text] [Related]  

  • 14. The rise and fall of Natrecor for congestive heart failure: implications for drug policy.
    Kesselheim AS; Fischer MA; Avorn J
    Health Aff (Millwood); 2006; 25(4):1095-102. PubMed ID: 16835191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advertisements. FDA orders Abbott to change misleading ads for Norvir.
    AIDS Policy Law; 2004 Jul; 19(12):9. PubMed ID: 15282864
    [No Abstract]   [Full Text] [Related]  

  • 16. Mandatory post marketing studies.
    Somberg J
    Am J Ther; 2007; 14(4):321. PubMed ID: 17667203
    [No Abstract]   [Full Text] [Related]  

  • 17. Lilly investigated in US over the marketing of olanzapine.
    Dyer O
    BMJ; 2007 Jan; 334(7586):171. PubMed ID: 17255580
    [No Abstract]   [Full Text] [Related]  

  • 18. The new drug marketing: a consumer protection perspective.
    Woodward D
    Food Drug Law J; 1996; 51(4):637-50. PubMed ID: 11797733
    [No Abstract]   [Full Text] [Related]  

  • 19. The marketplace can't give us the drug safety data we need.
    Avorn J
    MedGenMed; 2007 Feb; 9(1):29. PubMed ID: 17435636
    [No Abstract]   [Full Text] [Related]  

  • 20. Economic outcomes of antipsychotic agents in a Medicaid population: traditional agents vs. risperidone.
    Nightengale BS; Crumly JM; Liao J; Lawrence BJ; Jacobs EW
    Psychopharmacol Bull; 1998; 34(3):373-82. PubMed ID: 9803771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.